)
)
)
Perseo Pharma is a biopharmaceutical company pioneering innovative metabolic therapies. The company has raised USD 12 million from private investors, including a U.S. patient advocacy organization and a corporate fund. We are currently raising our USD 9M Series A, for which we have signed a Term Sheet with a US investor. Perseo's proprietary platform technology enables the development of highly effective gut-restricted treatments for a range of metabolic disorders. The company is targeting conditions like Exocrine Pancreatic Insufficiency (EPI) and a family of rare diseases made of Intoxication-Type Inborn Errors of Metabolism. PER301, Perseo's lead compound for EPI (well established $1.5bn market in the US alone), is being developed in partnership with Nestlé Health Science. A significant commercial milestone for this collaboration was reached at the end of 2025.
Year Founded
2019
Next catalyst (value inflection) update
Phase Ib
Expected time of next catalyst update
Dec-27
City
Muttenz
Country
Switzerland
Company CEO or top company official
Dr. Yves Dudal, CEO
Development Phase of Primary Product
Pre-Clinical
Lead Product in Development
PER301, Best-in-Class Pancreatic Enzyme Replacement Therapy
Number of Unlicensed Products
3
Therapeutic Area
Metabolic Diseases
Website
https://perseo-pharma.com/
){kind=logo}
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}
){kind=logo}
